Public Science Value Capture Framework
Ensuring taxpayers benefit from research they fund through access and pricing equity.
This framework addresses the fundamental inequity where taxpayers fund biomedical research but then must 'buy back' the benefits through journal paywalls and premium drug prices. It analyzes the complete value chain from NIH basic research → university discoveries → private sector development → public access, identifying where value escapes public capture. The framework proposes mechanisms to ensure those who fund research can access its outputs without double-paying, while maintaining incentives for private sector translation. It particularly examines the 'last mile problem'—how patent protection (via Bayh-Dole Act) creates commercial interest to develop discoveries, but at the cost of temporary monopolies and higher prices. The framework also addresses international free-riding, where U.S. taxpayers bear disproportionate R&D costs for global drug safety testing.
- Taxpayers should not pay twice for research: first through grants, then through access barriers.
- Patent protection trades temporary higher prices for faster translation of basic discoveries.
- R&D costs should be proportionally borne by all beneficiaries, not concentrated on one nation's taxpayers.
- Value capture mechanisms must balance innovation incentives with public access rights.
- Map the Value ChainTrace taxpayer dollars from NIH grant → university research → publication → patent → drug development → patient purchase. Identify each point where value escapes public capture.Pro tipUse specific examples like Alzheimer's research where decades of public funding yield drugs patients must purchase at premium prices.WarningDon't oversimplify; recognize legitimate costs at each stage (clinical trials, manufacturing, distribution).
- Calculate the Double PaymentQuantify how much taxpayers pay for research access (journal subscriptions) and benefit purchase (drug premiums) beyond their initial funding contribution.Pro tipCompare U.S. vs. European drug prices for identical products to estimate R&D burden disparity.WarningAvoid ignoring legitimate value added by private sector in translation and distribution.
- Analyze International Free-RidingAssess how other developed nations benefit from U.S.-funded R&D while paying marginal costs, creating an unsustainable burden concentration.Pro tipExamine 'law of one price' violations in pharmaceuticals—why arbitrage doesn't equalize U.S./Europe price differences.WarningDon't assume other nations contribute zero; some have parallel research systems, just at different scales.
- Design Equitable Capture MechanismsPropose systems where public funders capture some upside: royalty streams, price controls post-patent, mandatory open access, international cost-sharing agreements.Pro tipLearn from NIH's new open-access policy (July 2025) requiring immediate free public access to taxpayer-funded research.WarningAvoid killing translation incentives; without profit potential, many discoveries never reach patients.
- Implement Burden-Shifting PoliciesAdvocate for mechanisms like trade negotiation leverage, drug reimportation allowances, and reference pricing to redistribute R&D costs globally.Pro tipStudy President Trump's executive order linking drug prices to trade/tariff policies as a real-world burden-shifting attempt.WarningPrepare for resistance from nations accustomed to free-riding on U.S. R&D expenditures.
Previous NIH director Monica Bertnoli mandated free public access to taxpayer-funded research by December 2025. Dr. Bhattacharya accelerated implementation to July 2025, eliminating the 'pay to read what you paid for' absurdity.
New sleep medications (DORAs) costing $300/month in U.S. but ~$50 in Europe, with price difference funding late-stage safety trials that benefit all nations. Americans effectively subsidize global drug safety verification.
Developed from the observation that taxpayers fund research through NIH grants, then pay journals to read results, then pay premium prices for drugs developed from that research. The framework originated from analyzing the irrationality of this system: 'Like giving money for supplies to build a home, someone else lives in it, and you need a ticket to see it.' It was further refined by examining President Trump's executive order on drug price equalization and the economics of international R&D burden-sharing.